医疗保险按服务收费项目中直接口服抗凝剂使用者和非使用者与出血相关的住院情况:患病率、负担及特征的差异

Bleeding-Related Hospitalizations Among Direct Oral Anticoagulant Users and Nonusers in Medicare Fee-For-Service: Variation in Prevalence, Burden, and Characteristics.

作者信息

Bazell Carol M, Alston Maggie N, Ganti Latha G, Chang Raymond C, Wilsey H Andrew, Leary Stephanie A, Fopalan Winston C, Baugh Christopher W

机构信息

Milliman, Inc., New York, NY, USA.

Department of Research, Orlando College of Osteopathic Medicine, Winter Garden, FL, USA.

出版信息

Adv Ther. 2025 Jul 22. doi: 10.1007/s12325-025-03287-4.

Abstract

INTRODUCTION

Bleeding-related hospitalizations represent a major burden for patients and the US healthcare system. Anticoagulant therapies pose a greater risk for bleeding, especially among the older Medicare population. Direct oral anticoagulants (DOACs) have become the most common type of oral anticoagulant used in Medicare due to their clinical advantages. This descriptive study examines the burden of bleeding-related hospitalizations among DOAC users and nonusers (with no evidence of anticoagulant or antiplatelet use) in Medicare fee-for-service (FFS).

METHODS

This was an observational retrospective cohort study of bleeding-related hospitalizations in Medicare FFS using the 2020-2022 Medicare 100% Research Identifiable Files. We used 2020-2021 pharmacy claims to classify beneficiaries into DOAC user and nonuser cohorts and 2021-2022 healthcare administrative claims to identify demographics, bleeding-related hospitalization characteristics, and outcomes.

RESULTS

Of 18.4 million Medicare FFS beneficiaries who met the study's enrollment requirements, 9.3% were assigned to the DOAC user cohort, 81.5% were assigned to the nonuser cohort, and 9.1% were excluded (non-DOAC anticoagulant-only or prescription antiplatelet-only users). The bleeding-related hospitalization rate was four times higher in the DOAC user cohort compared to the nonuser cohort (27.5 and 6.7 per 1000 beneficiaries, respectively). Gastrointestinal bleeding was the most common bleed type leading to hospitalization in both DOAC user and nonuser cohorts (64.6% and 55.4%, respectively), followed by intracerebral hemorrhage (21.3% and 34.5%, respectively), and other types of bleeding (14.2% and 10.1%, respectively). Characteristics and outcomes were similar between cohorts, with variation largely related to bleeding type.

CONCLUSION

This study demonstrated variations in use of DOACs and characteristics of bleeding-related hospitalizations and identified higher rates of bleeding-related hospitalizations among DOAC users compared to nonusers. Hospitalization characteristics and outcomes differed by bleeding type. These findings highlight the Medicare FFS burden of bleeding-related hospitalizations and opportunities for the improved detection and management of bleeding, particularly among DOAC users.

摘要

引言

与出血相关的住院治疗给患者和美国医疗保健系统带来了重大负担。抗凝治疗会带来更高的出血风险,尤其是在老年医疗保险人群中。直接口服抗凝剂(DOACs)因其临床优势,已成为医疗保险中最常用的口服抗凝剂类型。这项描述性研究调查了医疗保险按服务收费(FFS)中DOAC使用者和非使用者(无抗凝或抗血小板使用证据)中与出血相关的住院负担。

方法

这是一项使用2020 - 2022年医疗保险100%可识别研究文件对医疗保险FFS中与出血相关的住院治疗进行的观察性回顾性队列研究。我们使用2020 - 2021年药房报销记录将受益人分为DOAC使用者和非使用者队列,并使用2021 - 2022年医疗管理报销记录来确定人口统计学特征、与出血相关的住院特征和结局。

结果

在符合研究纳入要求的1840万医疗保险FFS受益人中,9.3%被分配到DOAC使用者队列,81.5%被分配到非使用者队列,9.1%被排除(仅使用非DOAC抗凝剂或仅使用处方抗血小板药物的使用者)。与非使用者队列相比,DOAC使用者队列中与出血相关的住院率高出四倍(分别为每1000名受益人中有27.5例和6.7例)。胃肠道出血是导致DOAC使用者和非使用者队列住院的最常见出血类型(分别为64.6%和55.4%),其次是脑出血(分别为21.3%和34.5%),以及其他类型的出血(分别为14.2%和10.1%)。各队列之间的特征和结局相似,差异主要与出血类型有关。

结论

本研究表明DOACs的使用情况以及与出血相关的住院特征存在差异,并确定DOAC使用者中与出血相关的住院率高于非使用者。住院特征和结局因出血类型而异。这些发现凸显了医疗保险FFS中与出血相关的住院负担,以及改善出血检测和管理的机会,特别是在DOAC使用者中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索